Novartis' Pluvicto unlocks substantial new patient pool
Novartis' radioligand therapy Pluvicto leaps ahead into earlier manifestations of prostate cancer, unlocking a substantially larger patient pool.
Novartis
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:Basel, Switzerland
Founded:1996
Website:www.novartis.com/
Recent News
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
Novartis has discontinued a mid-stage radioligand therapy program as Pluvicto continues to exceed sales expectations.
For Novartis' CEO, China deals aren't a strategy shift — just where the science is
Novartis' CEO says its latest China deals are not a strategy shift — just following where the science is.
Novartis climbs on upbeat drug sales as key readouts loom
Novartis stock climbed on upbeat Q2 drug sales as key readouts loom.
Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal
Novartis CEO explained why he ended his ADC holdout for the $1.5B Myricx deal.
Novartis slashes New Jersey workforce again, cutting 322 employees
Novartis slashes New Jersey workforce again, cutting 322 employees (reported by BioSpace)
Novartis dismisses 322 more staffers based out of US headquarters
Novartis dismisses 322 more staffers based out of US headquarters (reported by Fierce Pharma)
Fosun pays $32M to join Lilly and Novartis in psoriasis market
Fosun pays $32M to join Lilly and Novartis in psoriasis market — Fierce Biotech coverage of biopharma industry developments.
Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product
Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product
Novartis, Antares stars align in cancer deal that could top $1.9B
Novartis and Antares Therapeutics are shooting for the stars, launching a joint mission to develop small molecule oncology therapies.
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
Leadership Team
Vasant Narasimhan
Chief Executive Officer
Careers & Job Openings
No active job listings. Check back later.